Background: Eluforsen (previously known as QR-010) is a 33-mer antisense oligonucleotide under development for oral inhalation in cystic fibrosis (CF) patients with the delta F508 mutation. Previous work has shown that eluforsen restores CF transmembrane conductance regulator (CFTR) function in vitro and in vivo. To be effective, eluforsen has first to reach its primary target, the lung epithelial cells. Therefore, it has to diffuse through the CF airway surface layer (ASL), which in CF is characterized by the presence of thick and viscous mucus, impaired mucociliary clearance, and persistent infections. The goal of this study was to assess delivery of eluforsen through CF-like ASL. Methods and Results: First, air-liquid interface studies with cultured primary airway epithelial cells revealed that eluforsen rapidly diffuses through CF-like mucus at clinically relevant doses when nebulized once or repeatedly, over a range of testing doses. Furthermore, eluforsen concentrations remained stable in CF patient sputum for at least 48 hours, and eluforsen remained intact in the presence of various inhaled CF medications for at least 24 hours. When testing biodistribution of eluforsen after orotracheal administration in vivo, no differences in lung, liver, trachea, and kidney eluforsen concentration were observed between mice with a CF-like lung phenotype (ENaC-overexpressing mice) and control wild-type (WT) littermates. Also, eluforsen was visualized in the airway epithelial cell layer of CF-like muco-obstructed mice and WT littermates. Finally, studies of eluforsen uptake and binding to bacteria prevalent in CF lungs, and diffusion through bacterial biofilms showed that eluforsen was stable and not absorbed by, or bound to bacteria. In addition, eluforsen was found to be able to penetrate Pseudomonas aeruginosa biofilms. Conclusions: The thickened and concentrated CF ASL does not constitute a significant barrier for delivery of eluforsen, and feasibility of oral inhalation of eluforsen is supported by these data.
Background: Eluforsen (previously known as QR-010) is a 33-mer antisense oligonucleotide under development for oral inhalation in cystic fibrosis (CF) patients with the delta F508 mutation. Previous work has shown that eluforsen restores CF transmembrane conductance regulator (CFTR) function in vitro and in vivo. To be effective, eluforsen has first to reach its primary target, the lung epithelial cells. Therefore, it has to diffuse through the CF airway surface layer (ASL), which in CF is characterized by the presence of thick and viscous mucus, impaired mucociliary clearance, and persistent infections. The goal of this study was to assess delivery of eluforsen through CF-like ASL. Methods and Results: First, air-liquid interface studies with cultured primary airway epithelial cells revealed that eluforsen rapidly diffuses through CF-like mucus at clinically relevant doses when nebulized once or repeatedly, over a range of testing doses. Furthermore, eluforsen concentrations remained stable in CF patient sputum for at least 48 hours, and eluforsen remained intact in the presence of various inhaled CF medications for at least 24 hours. When testing biodistribution of eluforsen after orotracheal administration in vivo, no differences in lung, liver, trachea, and kidney eluforsen concentration were observed between mice with a CF-like lung phenotype (ENaC-overexpressing mice) and control wild-type (WT) littermates. Also, eluforsen was visualized in the airway epithelial cell layer of CF-like muco-obstructed mice and WT littermates. Finally, studies of eluforsen uptake and binding to bacteria prevalent in CF lungs, and diffusion through bacterial biofilms showed that eluforsen was stable and not absorbed by, or bound to bacteria. In addition, eluforsen was found to be able to penetrate Pseudomonas aeruginosa biofilms. Conclusions: The thickened and concentrated CF ASL does not constitute a significant barrier for delivery of eluforsen, and feasibility of oral inhalation of eluforsen is supported by these data.
Authors: Jung Soo Suk; Anthony J Kim; Kanika Trehan; Craig S Schneider; Liudmila Cebotaru; Owen M Woodward; Nicholas J Boylan; Michael P Boyle; Samuel K Lai; William B Guggino; Justin Hanes Journal: J Control Release Date: 2014-01-14 Impact factor: 9.776
Authors: Benjamin S Schuster; Anthony J Kim; Joshua C Kays; Mia M Kanzawa; William B Guggino; Michael P Boyle; Steven M Rowe; Nicholas Muzyczka; Jung Soo Suk; Justin Hanes Journal: Mol Ther Date: 2014-05-29 Impact factor: 11.454
Authors: Panagiotis Mastorakos; Adriana L da Silva; Jane Chisholm; Eric Song; Won Kyu Choi; Michael P Boyle; Marcelo M Morales; Justin Hanes; Jung Soo Suk Journal: Proc Natl Acad Sci U S A Date: 2015-06-29 Impact factor: 11.205
Authors: N N Sanders; S C De Smedt; E Van Rompaey; P Simoens; F De Baets; J Demeester Journal: Am J Respir Crit Care Med Date: 2000-11 Impact factor: 21.405
Authors: Ashley G Henderson; Camille Ehre; Brian Button; Lubna H Abdullah; Li-Heng Cai; Margaret W Leigh; Genevieve C DeMaria; Hiro Matsui; Scott H Donaldson; C William Davis; John K Sheehan; Richard C Boucher; Mehmet Kesimer Journal: J Clin Invest Date: 2014-06-02 Impact factor: 14.808
Authors: David B Hill; Paula A Vasquez; John Mellnik; Scott A McKinley; Aaron Vose; Frank Mu; Ashley G Henderson; Scott H Donaldson; Neil E Alexis; Richard C Boucher; M Gregory Forest Journal: PLoS One Date: 2014-02-18 Impact factor: 3.240
Authors: Yan Dang; Catharina van Heusden; Veronica Nickerson; Felicity Chung; Yang Wang; Nancy L Quinney; Martina Gentzsch; Scott H Randell; Hong M Moulton; Ryszard Kole; Aiguo Ni; Rudolph L Juliano; Silvia M Kreda Journal: Nucleic Acids Res Date: 2021-06-21 Impact factor: 16.971
Authors: Wren E Michaels; Cecilia Pena-Rasgado; Rusudan Kotaria; Robert J Bridges; Michelle L Hastings Journal: Proc Natl Acad Sci U S A Date: 2022-01-18 Impact factor: 11.205